Pulse nav.journalClub Debates activos Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

18FT807, a novel tau positron emission tomography imaging agent for Alzheimer's disease | Synapse

February 11, 2013

18FT807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

(18)FT807 demonstrates high affinity and selectivity to PHF-tau as well as favorable in vivo properties, making this a promising candidate as an imaging agent for AD.

Me gusta

Guardar

Compartir

Me gusta

Guardar

Compartir

Cite This Study

Xia et al. (Mon,) studied this question.

synapsesocial.com/papers/69de5e697ed287395e558a50 https://doi.org/https://doi.org/10.1016/j.jalz.2012.11.008

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly2007 · 169 citations
2Quantitative assessment of the density of neurofibrillary tangles and senile plaques in senile dementia of the Alzheimer type. Comparison of immunocytochemistry with a specific antibody and Bodian's protargol method1987 · 91 citations
3Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease1992 · 2,688 citations
418F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease2011 · 332 citations
5AZD2184: a radioligand for sensitive detection of β‐amyloid deposits2008 · 120 citations